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Purpose: The aim of the current study was to evaluate the effect of melatonin
administration on clinical, hormonal, inflammatory, and genetic parameters in women
with polycystic ovarian syndrome (PCOS).
Methods: The present randomized, double-blinded, placebo-controlled clinical trial
was conducted among 56 patients with PCOS, aged 18–40 years old. Subjects were
randomly allocated to take either 5mg melatonin supplements (n = 28) or placebo
(n = 28) twice a day for 12 weeks.
Results: Melatonin administration significantly reduced hirsutism (β −0.47; 95% CI,
−0.86, −0.09; P = 0.01), serum total testosterone (β −0.11 ng/mL; 95% CI, −0.21,
−0.02; P = 0.01), high-sensitivity C-reactive protein (hs-CRP) (β −0.61 mg/L; 95% CI,
−0.95, −0.26; P = 0.001), and plasma malondialdehyde (MDA) levels (β −0.25 µmol/L;
95% CI, −0.38, −0.11; P < 0.001), and significantly increased plasma total antioxidant
capacity (TAC) levels (β 106.07 mmol/L; 95% CI, 62.87, 149.28; P < 0.001) and total
glutathione (GSH) (β 81.05 µmol/L; 95% CI, 36.08, 126.03; P = 0.001) compared
with the placebo. Moreover, melatonin supplementation downregulated gene expression
of interleukin-1 (IL-1) (P = 0.03) and tumor necrosis factor alpha (TNF-α) (P = 0.01)
compared with the placebo.
Conclusions: Overall, melatonin administration for 12 weeks to women with PCOS
significantly reduced hirsutism, total testosterone, hs-CRP, and MDA, while increasing
TAC and GSH levels. In addition, melatonin administration reduced gene expression of
IL-1 and TNF-α.
Clinical Trial Registration: www.irct.ir, identifier IRCT2017082733941N9, Available
online at: https://www.irct.ir/trial/26051
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INTRODUCTION
Polycystic ovarian syndrome (PCOS) is a highly prevalent
endocrinopathy affecting up to 10% of premenopausal women
and essentially characterized by hyperandrogenism, reproductive
abnormalities, and ovulatory dysfunction (1). Although the
exact pathophysiology of PCOS is not yet fully recognized,
evidence suggests that hyperandrogenism plays a central role
in this syndrome (2, 3). Hyperandrogenism might occur due
to the inflammatory response of the abnormal ovarian theca
cells to free oxygen radicals (4). Furthermore, prior studies
have indicated that increased oxidative stress and elevated
inflammatory markers such as C-reactive protein (CRP) in
women with PCOS are correlated with obesity, insulin resistance,
and an increased risk of cardiovascular disease (CVD) (5, 6).
The majority of women with PCOS suffer from hirsutism, acne,
oligomenorrhea, and androgenic alopecia, which impair the
quality of life of these women (7).
Melatonin (N-acetyl-5-methoxytryptamine) is secreted by
the pineal gland (8). The circadian pattern of its secretion
is regulated by the biological clock within the hypothalamic
suprachiasmatic nucleus (9). Some of the major functions of
rhythmic secretion of melatonin in blood include regulation of
sleep, modulation of circadian rhythms (10), and involvement
in the body’s immune response (11). Melatonin is also a
powerful endogenous antioxidant (12), and its supplementation
has radical-scavenging and anti-inflammatory actions (13, 14).
Women with PCOS are often sub-fertile secondary to ovulatory
dysfunction, impaired quality of oocyte, and low endometrial
receptivity (15). In vitro fertilization (IVF) is recommended as an
assisted reproduction technology for infertile patients with PCOS
when patients do not respond to ovulation induction agents
(16). Current evidence suggests the involvement of melatonin in
ovarian physiology including ovulation, follicular development,
luteal function, and oocyte maturation. Furthermore, melatonin
deficiency seems to be involved in the pathophysiology of
PCOS (17). It has been shown that melatonin is an efficient
predictor of oocyte quality and IVF outcomes: indeed, its high
concentration correlates positively with a satisfactory quality of
oocytes (18). On the other hand, intra-follicular melatonin level
is significantly reduced in patients with PCOS (18). In addition,
Jain et al. (19) demonstrated that nocturnal melatonin levels in
women with PCOS are higher than in control subjects. Elevated
nighttime melatonin levels in PCOS have been explained by a
feedback mechanism due to its decreased concentration in the
ovarian follicles (20). So, women with PCOS who have high
oxidative stress are synthesizing more melatonin, probably in
an effort to eliminate extra free radicals (21). High melatonin
level in the ovarian follicle fluid is pivotal for ovulation, follicular
growth, and quality of oocyte, whereas reduced melatonin level
in follicular fluid may be responsible for decreased oocyte
quality and anovulation in these women (22). In a recent study,
melatonin and myo-inositol co-supplementation significantly
improved embryo and oocyte quality in women with PCOS
who were candidates for IVF, when compared with myo-inositol
alone (23). In addition, treatment with melatonin and myo-
inositol significantly improved ovarian stimulation protocols
and pregnancy outcomes in women who failed to conceive in
previous IVF cycles because of poor quality of the oocyte (24).
There is promising evidence showing the importance of
melatonin supplementation in patients with PCOS who are
candidates for IVF. However, whether melatonin has direct
benefits on hirsutism, hormonal profiles, and biomarkers of
inflammation/oxidative stress in these patients has not been
assessed yet. The present study was, therefore, carried out to
evaluate the effects of melatonin administration on clinical status,
hormonal profiles, oxidative stress biomarkers, inflammatory
factors, and gene expression related to inflammation in women
diagnosed with PCOS who were candidates for IVF.
MATERIALS AND METHODS
Trial Design and Participants’
Characteristics
This randomized, double-blinded, placebo-controlled trial was
registered in the Iranian website for registration of clinical trials
(http://www.irct.ir: IRCT2017082733941N9) and followed the
Declaration of Helsinki and Good Clinical Practice guidelines.
This trial was conducted among 56 women aged 18–40 years
old diagnosed with PCOS, based on the Rotterdam criteria
(25), who had been referred to the Kosar Clinic in Arak, Iran,
between August and December 2017. The study protocol was
approved by the ethics committee of Arak University of Medical
Sciences (AUMS). Written informed consent was obtained from
all participants prior to the intervention. Exclusion criteria were
as follows: pregnancy, breastfeeding, sleeping disorders, adrenal
hyperplasia, androgen-secreting tumors, hyperprolactinemia,
thyroid dysfunction, and/or diabetes at enrollment.
Supplementation
Initially, patients were randomly divided into two groups to
take either melatonin capsules (2 × 5 mg/day) (n = 28) or
placebo (n = 28) for 12 weeks. Melatonin and the placebo were
manufactured by Zahravi Pharmaceutical Company (Tabriz,
Iran) and Barij Essence Pharmaceutical Company (Kashan, Iran),
respectively. The placebo capsules were matched in color, shape,
size, packaging, smell, and taste with the melatonin capsules.
Due to a lack of evidence regarding the appropriate dosage of
melatonin for patients with PCOS, we used the following dose
of melatonin based on a previous published study in diabetic
patients with coronary heart disease (CHD) (26). All individuals
were taking metformin tablets at an initial dose of 500mg, which
was increased in a stepwise manner during the first 3 weeks to
a total of 1,500 mg/day (27). In addition, all individuals were
taking 10 mg/day medroxyprogesterone tablet from the 15th
until the 25th day of the menstrual cycle. Throughout the study,
the consumption of melatonin supplements and placebos was
assessed by asking subjects to return the medication containers
as well as sending a brief daily cell phone reminder to take
the supplements. Patients were instructed to have their regular
physical activity and not take any extra nutritional supplements
during the 12-week trial. All patients completed a 3-day food
record (a weekend and 2 weekdays) at the baseline of the
study, week 3, week 6, week 9, and the end of the intervention.
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Daily macro- and micronutrient intakes were calculated by
analyzing 3-day food records, using nutritionist IV software
(First Databank, San Bruno, CA).
Assessment of Outcomes
Malondialdehyde (MDA) change was considered as the primary
outcome. Serum total testosterone, sex hormone–binding
globulin (SHBG), high-sensitivity C-reactive protein (hs-CRP),
plasma nitric oxide (NO), total antioxidant capacity (TAC), total
glutathione (GSH), hirsutism, and gene expression related to
inflammation were recognized as the secondary outcomes.
Clinical Measures
Hirsutism was assessed using a modified Ferriman–Gallwey
(mFG) scoring system as 9 body areas, including the upper lip,
chin, chest, upper abdomen, lower abdomen, thighs, back, arm,
and buttocks, were investigated for hair, from 0 (no hair) to 4
(frankly virile) (28, 29).
Biochemical Assessment
Fasting blood samples (15ml) were collected at baseline and
the end of the intervention at the Arak reference laboratory.
Blood samples were immediately centrifuged (Hettich D-78532,
Tuttlingen, Germany) at 3,500 rpm for 10min to separate serum.
Then, the samples were stored at −80◦C at the AUMS reference
laboratory until further analysis. Whole blood samples were
used to check gene expression; serum samples to evaluate total
testosterone, SHG, and hs-CRP; and plasma samples to measure
NO, TAC, GSH, and MDA. Serum total testosterone and SHBG
were measured using commercial validated kits (DiaMetra,
Milano, Italy) with inter- and intra-assay coefficient variances
(CVs) below 6.5%. Serum hs-CRP concentrations were quantified
using a commercial ELISA kit (LDN, Nordhorn, Germany) with
inter- and intra-assay CVs below 7%. The plasma NO was
measured using the Griess method (30), TAC concentrations
using the Benzie and Strain method (31), GSH using the Beutler
method (32), and MDA concentrations of thiobarbituric acid–
reactive substances using a spectrophotometric test with CVs
below 5%. Measurements of hormonal profiles and biomarkers
of inflammation and oxidative stress were performed in a blinded
fashion, in duplicate, in pairs (pre/post-intervention) at the same
time, in the same analytical run, and in random order to reduce
systematic error and inter-assay variability.
Isolation of Lymphocyte, RNA Extraction,
and cDNA Synthesis
Whole blood samples were collected in anticoagulant EDTA
tubes. Lymphocytes were isolated using 50% Percoll solution
(Sigma-Aldrich, Dorset, UK) gradient by centrifugation for
20min at 3,000 rpm at 4◦C (33). Total RNA was extracted
using the acid guanidinium–phenol–chloroform procedure and
the application of RNX
TM
-plus reagent (Cinnacolon, Tehran,
Iran) following manufacturer’s instructions. RNAs were treated
with DNase I (Fermentas, Lithuania) for the elimination of
any genomic DNA contamination. Concentration, integration,
and purity of RNA samples were determined by spectrometry
and gel electrophoresis. Three micrograms of total RNA
was used for cDNA synthesis with random hexamer and
oligo(dT)18 primers through RevertAid
TM
Reverse Transcriptase
(Fermantase, Canada) in a total of 20-µl reaction mixture (33).
Real-Time PCR Analysis
Appropriate primers were designed for interleukin-1 (IL-1),
IL-8, tumor necrosis factor-α (TNF-α), transforming growth
factor beta (TGF-β), and vascular endothelial growth factor
(VEGF), and glyceraldehyde-3 phosphate dehydrogenase as the
internal control (housekeeping gene; Table 1). Quantitative real-
time PCR was performed using LightCycler R© 96 sequence
detection systems (Roche Diagnostics, Rotkreuz, Switzerland)
with the application of 4 µl of 5× EVA GREEN I master
mix (Salise Biodyne, Japan), 10 ng cDNA, and 200 nM each
of forward and reverse primers in a final volume of 20 µl.
The PCR was performed through the following instruction: an
initial denaturation at 95◦C for 10min, followed by 40 cycles
of denaturation at 95◦C for 10 s, annealing at 54–62.1◦C for
15 s, and extension at 72◦C for 30 s. The specificity of PCR
products was evaluated by 1.5% agarose gel electrophoresis and
melting curve analysis. All experiments were performed at least
in triplicate.
Sample Size
To determine sample size, we used a randomized clinical trial
(RCT) sample-size formula where type I (α) and type II errors (β)
were 0.05 and 0.20 (power= 80%). Based on a previous RCT (26),
we used a standard deviation of 0.30 µmol/L and a difference in
mean (d) of 0.24 µmol/L, considering MDA as the key variable.
The calculation indicated that 25 participants were required in
each group. Assuming a dropout of five patients per group, the
final sample size was determined to be 30 participants per group.
Randomization
Study participants were randomized using computer-generated
random numbers. Randomization and allocation were concealed
TABLE 1 | Specific primers used for real-time quantitative PCR.
Gene Primer Product
size (bp)
Annealing
temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
IL-1 F: GCTTCTCTCTGGTCCTTGG 174 56
R: AGGGCAGGGTAGAGAAGAG
IL-8 F: GCAGAGGGTTGTGGAGAAGT 150 56
R: ACCCTACAACAGACCCACAC
TNF-α F: GTCAACCTCCTCTCTGCCAT 188 52
R: CCAAAGTAGACCTGCCCAGA
TGF-β F: TTGAGACTTTTCCGTTGCCG 227 56
R: CGAGGTCTGGGGAAAAGTCT
VEGF F: CTTCTGAGTTGCCCAGGAGA 216 54
R: CTCACACACACACAACCAGG
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL-1, interleukin-1; IL-8,
interleukin-8; TNF-α, tumor necrosis factor alpha; TGF-β, transforming growth factor
beta; VEGF, vascular endothelial growth factor.
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FIGURE 1 | Summary of patient flow diagram.
from both researchers and patients until the completion of final
analyses. The randomized allocation sequence, enrollment of
participants, and allocation to interventions were conducted by a
trained staff at the clinic. Another person, who was not involved
in the trial and not aware of random sequences, assigned the
subjects to the numbered bottles of capsules.
Statistical Analyses
The Kolmogorov–Smirnov test was done to determine the
normality of data. Differences in dietary intakes and gene
expression were detected using independent-sample t-tests
between treatment groups. Multiple linear regression models
were used to assess the treatment effects on study outcomes, after
adjusting for confounding parameters including age and BMI.
The significance of the treatment effects was presented as the
mean differences with 95% confidence interval. P-values < 0.05
were considered statistically significant. All statistical analyses
were done using the Statistical Package for Social Science version
18 (SPSS Inc., Chicago, Illinois, USA).
RESULTS
During the study period, four participants dropped out of the
study due to personal reasons (two participants in each group;
TABLE 2 | General characteristics of study participantsa.
Placebo group
(n = 28)
Melatonin group
(n = 28)
Pb
Age (y) 28.3 ± 2.3 28.7 ± 2.1 0.76
Height (cm) 160.0 ± 2.9 161.0 ± 2.5 0.30
Weight at study baseline (kg) 74.8 ± 8.9 75.1 ± 11.0 0.90
Weight at end of trial (kg) 74.5 ± 8.9 74.7 ± 10.9 0.92
Weight change (kg) −0.3 ± 0.9 −0.4 ± 1.1 0.79
BMI at study baseline (kg/m2) 29.2 ± 3.5 29.1 ± 4.6 0.92
BMI at end of trial (kg/m2) 29.1 ± 3.4 29.0 ± 4.6 0.91
BMI change (kg/m2) −0.1 ± 0.3 −0.1 ± 0.4 0.84
aData are means ± SDs.
bObtained from independent t-test.
Figure 1). Fifty-six participants [placebo (n= 28) and melatonin
(n= 28)] completed the trial.
Anthropometric measures were not statistically different
between intervention groups (Table 2).
There was no statistically significant difference in dietary
macro- and micro-nutrient intakes between the melatonin and
placebo groups (Table 3).
Melatonin administration significantly reduced hirsutism (β
−0.47; 95% CI,−0.86,−0.09; P= 0.01), serum total testosterone
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TABLE 3 | Mean dietary intakes of study participants at baseline, week 3, week 6,
and week 9, and the end of the intervention.
Placebo group
(n = 28)
Melatonin group
(n = 28)
Pa
Energy (kcal/d) 2,228 ± 311 2,273 ± 300 0.58
Carbohydrates (g/d) 293.7 ± 70.1 311.7 ± 62.3 0.31
Protein (g/d) 89.1 ± 14.1 85.2 ± 12.2 0.28
Fat (g/d) 80.2 ± 11.1 79.8 ± 16.0 0.90
SFAs (g/d) 25.0 ± 5.7 24.9 ± 5.4 0.96
PUFAs (g/d) 25.4 ± 5.1 24.7 ± 6.6 0.63
MUFAs (g/d) 22.0 ± 5.0 22.4 ± 6.1 0.76
Cholesterol (mg/d) 250.6 ± 117.3 215.7 ± 101.7 0.24
TDF (g/d) 17.2 ± 4.6 18.9 ± 4.9 0.19
Data are means ± SDs.
aObtained from independent t-test.
MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs,
saturated fatty acids; TDF, total dietary fiber.
(β −0.11 ng/mL; 95% CI, −0.21, −0.02; P = 0.01), hs-CRP (β
−0.61mg/L; 95%CI,−0.95,−0.26; P= 0.001), and plasmaMDA
levels (β −0.25 µmol/L; 95% CI, −0.38, −0.11; P < 0.001), and
significantly increased plasma TAC levels (β 106.07 mmol/L; 95%
CI, 62.87, 149.28; P < 0.001) and GSH (β 81.05 µmol/L; 95% CI,
36.08, 126.03; P = 0.001) compared with the placebo (Table 4).
Melatonin supplementation did not affect plasma NO and serum
SHBG levels.
Melatonin supplementation downregulated gene expression
of IL-1 (P = 0.03) and TNF-α (P = 0.01) compared with the
placebo (Figure 2). Melatonin supplementation did not influence
the gene expression of IL-8, TGF-β, and VEGF.
DISCUSSION
In this investigation, we evaluated the impact of melatonin
administration for 12 weeks on clinical status, hormonal profiles,
oxidative stress biomarkers, inflammatory factors, and gene
expression related to inflammation in women with PCOS
who were candidates for IVF. Our findings depicted that
melatonin administration for 12 weeks to women with PCOS
significantly reduced hirsutism, total testosterone, hs-CRP, and
MDA, while increasing TAC and GSH levels. In addition,
melatonin administration reduced gene expression of IL-1 and
TNF-α. Melatonin, in humans, is produced in the pineal gland,
cutaneous tissue, ovary, retina, and gastrointestinal system,
though its rhythmic synthesis occurs only in the pineal gland
(34). Melatonin is detectable in everybody’s compartment, such
as in the pre-ovulatory follicular fluid, where its level is
remarkably higher than that in the serum (35). Although it has
been considered that the melatonin in human pre-ovulatory
follicular fluid is derived from the body circulation, it may also
be produced in the ovary (granulosa and oocyte cells) (36).
There is current evidence demonstrating elevated melatonin
concentrations in the luteal phase compared with the follicular
phase of the human menstrual cycle (37). Melatonin directly
stimulates the production of progesterone by granulosa cells or
luteal cells and might act at the ovary level to regulate luteal
function (18).
Effects on Clinical Status and Hormonal
Profiles
We found that melatonin consumption for 12 weeks in
women with PCOS significantly decreased hirsutism and
total testosterone levels yet did not influence SHBG values.
Hyperandrogenism, the hallmark of PCOS, is a consequence
of excessive androgen production by the abnormal ovarian
theca cells and the augmented activity and expression of
various enzymes involved in the production of steroids (2, 38).
Furthermore, adrenal glands contribute to hyperandrogenism,
as evidenced by raised levels of dehydroepiandrosterone sulfate
(DHEAS) (39). Existing evidence suggests that decreased
androgen levels are associated with an improvement in ovulatory
functions, reducing hirsutism, and enhancing health-related
quality of life (40, 41). It has been shown that the ovary (oocyte
and granulosa cells) can produce melatonin and that melatonin
receptors are detected in the membrane of human luteal and
granulosa cells (20). Women with PCOS have significantly
elevated melatonin concentrations and hyperandrogenemia
along with an elevated number of atretic follicles (19). After 6
months of supplementation, melatonin significantly improved
menstrual irregularities and biochemical hyperandrogenism in
women with PCOS through a direct, insulin-independent effect
on the ovary (42). In another study, melatonin administration
to a PCOS mouse model potentially induced oocyte nuclear
maturation and guaranteed fertilization potential (43).Melatonin
is favored toward the treatment of PCOS via its influence on
the production of steroids, thereby modulating ovulation and
reducing insulin resistance and dyslipidemia (44). Overall, there
are different parameters, including participants’ characteristics,
pancreatic beta-cell function, higher dose of melatonin, or
longer period of intervention, that can provide appropriate
circulating levels of melatonin necessary for improving SHBG
levels. However, we were not able to assess circulating levels of
melatonin in the present study. Perhaps if the dose or duration
of melatonin supplementation had been increased, the results of
SHBG would have been significant.
Effects on Biomarkers of Inflammation and
Oxidative Stress
Our findings showed that melatonin intake after 12 weeks
in women with PCOS significantly decreased serum hs-
CRP and plasma MDA, and significantly increased plasma
GSH and TAC levels. Moreover, melatonin consumption
downregulated IL-1 and TNF-α gene expression in PBMCs of
women with PCOS, but did not affect gene expression of IL-8,
TGF-β, and VEGF. Previous studies have shown a promising
effect of melatonin on inflammation and oxidative stress.
Mistraletti et al. (45) demonstrated that 6 mg/day melatonin
administration to critically ill patients significantly ameliorated
TAC levels. Melatonin intake at a dosage of 5 mg/day for
8 weeks among people with metabolic syndrome reduced
MDA levels and enhanced catalase activity (46). Recently,
we depicted in another study that the administration of 10
mg/day melatonin for 12 weeks to diabetic people with ischemic
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TABLE 4 | Metabolic profiles at baseline and after the 12-week intervention in women with polycystic ovary syndrome who received either melatonin supplements or
placeboa.
Variables Placebo group
(n = 28)
Melatonin group
(n = 28)
Difference in outcome measures
between melatonin and placebo groupsa
Baseline Week 12 Baseline Week 12 β (95% CI) Pb
Total testosterone (ng/mL) 1.1 ± 0.3 1.1 ± 0.4 1.0 ± 0.2 0.9 ± 0.2 −0.11 (−0.21, −0.02) 0.01
SHBG (nmol/L) 39.3 ± 8.4 39.2 ± 8.3 37.7 ± 7.7 38.9 ± 8.0 1.24 (−0.31, 2.80) 0.11
mFG scores 11.5 ± 2.7 11.2 ± 2.6 12.0 ± 2.4 11.2 ± 2.3 −0.47 (−0.86, −0.09) 0.01
hs-CRP (mg/L) 4.1 ± 2.1 4.3 ± 1.9 4.3 ± 1.7 3.9 ± 1.8 −0.61 (−0.95, −0.26) 0.001
NO (µmol/L) 29.9 ± 2.9 29.5 ± 2.8 28.1 ± 2.5 28.3 ± 2.6 0.26 (−0.73, 1.26) 0.59
TAC (mmol/L) 1,011.2 ± 92.4 1,000.7 ± 100.8 1,030.0 ± 85.0 1,119.3 ± 102.7 106.07 (62.87, 149.28) < 0.001
GSH (µmol/L) 525.7 ± 62.6 533.4 ± 63.2 568.8 ± 133.5 655.5 ± 167.9 81.05 (36.08, 126.03) 0.001
MDA (µmol/L) 2.6 ± 0.4 2.7 ± 0.5 2.6 ± 0.5 2.5 ± 0.5 −0.25 (−0.38, −0.11) < 0.001
Data are means ± SDs.
a”Outcome measures” refers to the change in values of measures of interest between baseline and week 12. β [difference in the mean outcome measures between treatment groups
(melatonin group = 1 and placebo group = 0)].
bObtained from multiple-regression model (adjusted for baseline values of each biochemical variables, age, and baseline BMI).
GSH, total glutathione; hs-CRP, high-sensitivity C-reactive protein; mFG, modified Ferriman–Gallwey; MDA, malondialdehyde; NO, nitric oxide; SHBG, sex hormone–binding globulin;
TAC, total antioxidant capacity.
FIGURE 2 | Fold change (means ± SDs) of gene expression levels for IL-1, IL-8, TNF-α, TGF-β, and VEGF were compared using independent t-test (N = 28 in each
group) between women with polycystic ovary syndrome receiving melatonin supplements and those receiving placebo. IL-1, interleukin-1; IL-8, interleukin-8; PCOS,
polycystic ovary syndrome; TNF-α, tumor necrosis factor alpha; TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor.
heart disease had favorable impacts on inflammatory status
and oxidative stress parameters (26). Pakravan et al. (47)
also found that supplementation with 10 mg/day melatonin
significantly decreased CRP levels in people with non-alcoholic
fatty liver disease. In a recent meta-analysis conducted by
Akbari et al. (48), melatonin supplementation decreased
systemic inflammatory markers in patients with metabolic
diseases. However, melatonin consumption (6 mg/day) in
obese women for 40 days did not influence hs-CRP, TAC, and
MDA levels (49). The varieties in study design, population
characteristics, dosage of melatonin taken, and duration of
intervention might explain the discrepancies among the results
of published trials. Insulin resistance might be correlated with
a specific ultrasound pattern in patients with PCOS (50). In
addition, increased oxidative stress and inflammatory status
are correlated with an elevated risk of CVD, diabetes mellitus,
hyperandrogenism, and insulin resistance in PCOS (6, 51).
Both oxidative stress and PCOS have also been involved
in several aspects of female reproduction (52). Melatonin
can attenuate inflammatory status and oxidative damage via
modulating the function of antioxidative enzymes, inhibiting
nuclear factor-kappaB activation, enhancing glutathione
synthesis, and directly scavenging free radicals in the inflamed
tissues (53, 54).
This study had a few limitations. Due to a funding shortage,
we were not able to measure serum melatonin and/or urinary
6-sulfatoxymelatonin (its main excretory metabolite) to assess
precisely the compliance of study participants. This limitation
has been considered in the interpretation of our findings.
In addition, we were unable to determine the impacts of
melatonin administration on other biomarkers of oxidative stress
and inflammation. Also, we did not evaluate biomarkers of
inflammation and oxidative stress in the ovary. Measurement
of hirsutism as a clinical finding in the current study is
undervalued; however, we did not evaluate menstrual cyclicity
before and after the treatment, which is one of the most
pivotal outcomes for the health and reproduction of women
with PCOS.
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Overall, this RCT suggests that melatonin administration for
12 weeks to women with PCOS might reduce hirsutism, total
testosterone, hs-CRP, and MDA, while increasing TAC and GSH
levels. In addition, melatonin administration might reduce gene
expression of IL-1 and TNF-α.
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